



# PKR JAIN HEALTHCARE INSTITUTE NASIRPUR, Hissar Road, AMBALA CITY- (Haryana)

# A PIONEER DIAGNOSTIC CENTRE

**■** 0171-2532620, 8222896961 **■** pkrjainhealthcare@gmail.com

REPORTING DATE

: 09/Jul/2024 06:12PM

**NAME** : Mrs. SIMRAN

**AGE/ GENDER** : 23 YRS/FEMALE **PATIENT ID** : 1541153

**COLLECTED BY** : 122407070006 REG. NO./LAB NO.

REFERRED BY **REGISTRATION DATE** : 07/Jul/2024 12:08 PM BARCODE NO. **COLLECTION DATE** : 07/Jul/2024 12:13PM : 12503473

**CLIENT ADDRESS** : NASIRPUR, HISSAR ROAD, AMBALA CITY - HARYANA

: P.K.R JAIN HEALTHCARE INSTITUTE

Value Unit **Biological Reference interval** Test Name

# **ENDOCRINOLOGY** QUADRUPLE MARKER MATERNAL SCREENING

### **QUADRUPLE MARKER**

CLIENT CODE.

## **PATEINT SPECIFICATIONS**

DATE OF BIRTH 27-01-2001

MATERNAL AGE 23.8 YEARS WEIGHT 52 Kg

ETHNIC ORIGIN **ASIAN ASIAN** 

H/O IVF **ABSENT** H/O INSULIN DEPENDANT DIABETES **ABSENT** H/O SMOKING ABSENT

H/O TRISOMY 21 SCREENING **ABSENT** 

### **ULTRA SOUND SCAN DETAILS**

DATE OF ULTRASOUND 05-06-2024

by ULTRASOUND SCAN

**ULTRASOUND SCAN DETAILS** METHOD FOR GESTATION AGE ESTIMATION

by ULTRASOUND SCAN FOETUS (NOS)

by ULTRASOUND SCAN

GA ON THE DAY OF SAMPLE COLLECTION 20.1 **WEEKS** 

by ULTRASOUND SCAN

29.6 26 - 52 **BIPARIETAL DIAMETER (BPD)** mm by ULTRASOUND SCAN

#### **QUADRUPLE TEST - BIOCHEMICAL MARKERS**

ALPHA FETO PROTEIN (AFP) 44.6 ng/mL

PRENATAL SCREENING: SERUM

by CLIA (CHEMILUMINESCENCE IMMUNOASSAY)

1.7 ESTRIOL (uE3) UNCONJUGATED ng/mL

by CLIA (CHEMILUMINESCENCE IMMUNOASSAY)

12393 mIU/mL BETA HCG by CLIA (CHEMILUMINESCENCE IMMUNOASSAY)

CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY)



440 Dated 17.5.2012 u/s 80 G OF INCOME TAX ACT. PAN NO. AAAAP1600. REPORT ATTRACTS THE CONDITIONS PRINTED OVERLEAF (P.T.O.)





# PKR JAIN HEALTHCARE INSTITUTE NASIRPUR, Hissar Road, AMBALA CITY- (Haryana)

## A PIONEER DIAGNOSTIC CENTRE

**NAME** : Mrs. SIMRAN

AGE/ GENDER : 23 YRS/FEMALE **PATIENT ID** : 1541153

**COLLECTED BY** REG. NO./LAB NO. : 122407070006

REFERRED BY **REGISTRATION DATE** : 07/Jul/2024 12:08 PM BARCODE NO. : 12503473 **COLLECTION DATE** : 07/Jul/2024 12:13PM

CLIENT CODE. : P.K.R JAIN HEALTHCARE INSTITUTE REPORTING DATE : 09/Jul/2024 06:12PM

**CLIENT ADDRESS** : NASIRPUR, HISSAR ROAD, AMBALA CITY - HARYANA

Test Name	Value	Unit	Biological Reference interval
INHIBIN A by CLIA (CHEMILUMINESCENCE IMMUNOASSAY) MULTIPLE OF MEDIAN (MOM) VALUES	144.2	pg/mL	
AFP MOM by CLIA (CHEMILUMINESCENCE IMMUNOASSAY)	0.66		
ESTRIOL (uE3) MOM by CLIA (CHEMILUMINESCENCE IMMUNOASSAY)	0.78		
BETA HCG MOM by CLIA (CHEMILUMINESCENCE IMMUNOASSAY)	0.63		
INHIBIN A MOM by CLIA (CHEMILUMINESCENCE IMMUNOASSAY)	0.79		

### TRISOMY 21 SCREENING (DOWNS SYNDROME) RISK ASSESSMENT

TRISOMY 21 SCREENING RISK RESULT **NEGATIVE (-ve) NEGATIVE (-ve)** 

by CLIA (CHEMILUMINESCENCE IMMUNOASSAY)

TRISOMY 21 AGE RISK 1:7578 NEGATIVE (-ve)

by CLIA (CHEMILUMINESCENCE IMMUNOASSAY)

TRISOMY 21 BIOCHEMICAL RISK 1:1434 NEGATIVE (-ve) RISK CUT OFF 1:270

by CLIA (CHEMILUMINESCENCE IMMUNOASSAY)

TRISOMY 18 SCREENING RISK ASSESSMENT

TRISOMY 18 AGE RISK **NEGATIVE** (-ve)

by CLIA (CHEMILUMINESCENCE IMMUNOASSAY)

TRISOMY 18 SCREENING RISK < 1:10000 NEGATIVE (-ve) RISK CUT OFF 1:100

by CLIA (CHEMILUMINESCENCE IMMUNOASSAY)

#### **NEURAL TUBE DEFECTS SCREENING RISK ASSESSMENT**

NEURAL TUBE DEFECT SCREENING RISK **NEGATIVE (-ve)** RISK CUT OFF 1:50

by CLIA (CHEMILUMINESCENCE IMMUNOASSAY)

SPINA BIFIDA/ANENCEPHALY SCREENING RISK < 1:10000 NEGATIVE (-ve) RISK CUT OFF 1:50

by CLIA (CHEMILUMINESCENCE IMMUNOASSAY)

#### **INTERPRETATION:**

1. Multiple marker serum has become standard tool used in obstetrica care to identify pregnancies that may have increased risk for certain birth defects such as NEURALTUBE DEFECTS (NTD'S), DOWN'S SYNDROME (TRISOMY 21) AND TRISOMY 18. The screen is performed by measuring analytes in maternal serum that are produced by the fetus and the placenta. The analytes values along with maternal demographic information such as age, weight, gestational age, diabetic status, and race are used together in mathematical model to derive risk estimate.

2. The laboratory establishes a specific cut off for each condition, which classifies each screen as either screen-positive or screen-negative.

3.A screen-positive result indicates that the value obtained exceeds the established cut off.



CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY)



440 Dated 17.5.2012 u/s 80 G OF INCOME TAX ACT. PAN NO. AAAAP1600. REPORT ATTRACTS THE CONDITIONS PRINTED OVERLEAF (P.T.O.)





# PKR JAIN HEALTHCARE INSTITUTE NASIRPUR, Hissar Road, AMBALA CITY- (Haryana)

## A PIONEER DIAGNOSTIC CENTRE

**NAME** : Mrs. SIMRAN

AGE/ GENDER : 23 YRS/FEMALE **PATIENT ID** : 1541153

**COLLECTED BY** : 122407070006 REG. NO./LAB NO.

REFERRED BY **REGISTRATION DATE** : 07/Jul/2024 12:08 PM BARCODE NO. : 12503473 **COLLECTION DATE** : 07/Jul/2024 12:13PM

CLIENT CODE. : P.K.R JAIN HEALTHCARE INSTITUTE REPORTING DATE : 09/Jul/2024 06:12PM

**CLIENT ADDRESS** : NASIRPUR, HISSAR ROAD, AMBALA CITY - HARYANA

Test Name Value Unit **Biological Reference interval** 

4. The estimated risk calculation and screen results are dependent on accurate information for gestation, maternal age, race, IDD, and weight. Inaccurate information can lead to significant alterations in the estimated risk. In particular, erroneous assessment of gestational age can result in false-positive or false-negative screen results. Because of its increased accuracy, we therefore recommend determination of gestational age by ultrasound, rather than by last menstural period (LMP), When possible.

4.A negative screen indicates a lower probability of having a baby with TRISOMY 21 ,TRISOMY 18 and NEURAL TUBE DEFECTS, but does not completely exclude the possibility.

5.A positive screen on the contrary only indicates a higher probability of having a baby with TRISOMY 21, TRISOMY 18 and NEURAL TUBE DEFECTS, and needs confirmation by cytogenetic studies and/or level II scan.

#### NOTE:

1. Triplet and higher multiple pregnancies cannot be interpreted

2. The reportable range for Trisomy 21, Trisomy 18 and NTD: >1:50 to < 1:10000

3.TRISOMY 21: HIGH RISK: >1:50 - 1:250

4.TRISOMY 18: HIGH RISK: >1:50 - 1:100

5.NEURAL TUBE DEFECT (NTD'S): HIGH RISK: >1:50

6.Biological markers evaluated in this test have marked as H(HIGH) or L(LOW) since there is wide variation in Alpha Fetoprotein, HCG and Unconjugated Estriol ranges depending upon gestational age. "In Range" and "Out of Range" columns are not applicable for the parameters appearing in Multiple of Median (MoM) and Risk calcultion.

7.Individually, Alpha Fetoprotein or HCG or unconjugated Estriol levels do not correlate with risk assessment of Trisomy 18, Trisomy 21 or Neural Tube Defects

\*\*\* End Of Report \*\*\*



CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY)



440 Dated 17.5.2012 u/s 80 G OF INCOME TAX ACT. PAN NO. AAAAP1600. REPORT ATTRACTS THE CONDITIONS PRINTED OVERLEAF (P.T.O.)